APA (7th ed.) Citation

Susiriwatananont, T., Wongkraisri, C., Dajsakdipon, T., Supavavej, A., Dechaphunkul, A., Sunpaweravong, P., . . . Tyagi, A. (2025). Clinical Outcomes of HER2‐Low Versus HER2‐Zero in HR‐Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study. International Journal of Breast Cancer, 2025, 1. https://doi.org/10.1155/ijbc/5597051

Chicago Style (17th ed.) Citation

Susiriwatananont, Thiti, et al. "Clinical Outcomes of HER2‐Low Versus HER2‐Zero in HR‐Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study." International Journal of Breast Cancer 2025 (2025): 1. https://doi.org/10.1155/ijbc/5597051.

MLA (9th ed.) Citation

Susiriwatananont, Thiti, et al. "Clinical Outcomes of HER2‐Low Versus HER2‐Zero in HR‐Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study." International Journal of Breast Cancer, vol. 2025, 2025, p. 1, https://doi.org/10.1155/ijbc/5597051.